Share
inherited neuromuscular diseases: translation from pathomechanisms to therapies
Carmen Espinós
(Illustrated by)
·
Vicente Felipo
(Illustrated by)
·
Francesc Palau
(Illustrated by)
·
Springer
· Paperback
inherited neuromuscular diseases: translation from pathomechanisms to therapies - Espinós, Carmen ; Felipo, Vicente ; Palau, Francesc
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My Wishlists
Origin: U.S.A.
(Import costs included in the price)
It will be shipped from our warehouse between
Monday, June 03 and
Wednesday, June 19.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "inherited neuromuscular diseases: translation from pathomechanisms to therapies"
This volume contains the text of the presentations delivered at the International Symposium on Rare Diseases "Inherited Neuromuscular Diseases: Translation from Pathomechanisms to Therapies", held in Valencia, Spain, from November 16 to 18, 2008. The symposium represents a part of the continuous efforts on dif- sion of science to the society of the Cátedra Santiago Grisolía and the Fundación Ciudad de las Artes y las Ciencias -Comunitat Valenciana. More than 200 inter- tional scientists from different countries of Europe, the USA, and Australia attended the meeting. The venue was the Auditorium of the Science Museum Príncipe Felipe. Ten years ago Alan Emery wrote in the preface of Neuromuscular Disorders: Clinical and Molecular Genetics the following comments: "It has been estimated that more than one person in every 3,000 has a serious disabling inherited n- romuscular disorder. The suffering caused by these disorders is considerable, but, until the last decade or so, virtually nothing was known of their pathogenesis. Any rationale approach to treatment was therefore out of the question. However, matters are now changing rapidly. The genes for many of these disorders have been localised and characterised and their gene products identi ed and studied. The detection of preclinical disease, the identi cation of heterozygous carriers and prenatal di- nosis are all becoming possible, and, hopefully, effective treatments may no be too far distant.
